Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus

Aim. To investigate the efficacy and safety of glimepiride as initial mono-therapy in type 2 diabetes patients (T2DM). Materials and Methods. This is a multi-center, open-label prospective observational study. 245 treatment-naive T2DM patients, who had not achieved glycemic goals on lifestyle the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander Sergeevich Ametov, Fatima Totrazovna Abaeva
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2013
Materias:	hemoglobin a1c diabetes mellitus glimepiride hypoglycemic agents Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/3dd493e044804230a221fbe2dc9499dc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3dd493e044804230a221fbe2dc9499dc
record_format	dspace
spelling	oai:doaj.org-article:3dd493e044804230a221fbe2dc9499dc2021-11-14T09:00:18ZEfficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus2072-03512072-037810.14341/DM2013495-100https://doaj.org/article/3dd493e044804230a221fbe2dc9499dc2013-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6276https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To investigate the efficacy and safety of glimepiride as initial mono-therapy in type 2 diabetes patients (T2DM). Materials and Methods. This is a multi-center, open-label prospective observational study. 245 treatment-naive T2DM patients, who had not achieved glycemic goals on lifestyle therapy during first 12 weeks after the diagnosis, were enrolled in this study. Anti-diabetes treatment was initiated with glimepiride and continued during the 6-month follow-up period. Prescription of the initial dose (1 mg per day) and further dose adjustments were carried out by the attending physician in accordance with the glimepiride data sheet. Dynamics of HbA1c, fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPPG), weight and waist circumference, as well as the incidence of hypoglycemia were the evaluated parameters. Results. The baseline HbA1c (mean: 7.9?0.5%; female: 7.8?0.4% ; male: 8.0?0.6%) was significantly reduced at week 12 (mean 7.2?0.6%, pAlexander Sergeevich AmetovFatima Totrazovna AbaevaEndocrinology Research Centrearticlehemoglobin a1cdiabetes mellitusglimepiridehypoglycemic agentsNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 16, Iss 4, Pp 95-100 (2013)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	hemoglobin a1c diabetes mellitus glimepiride hypoglycemic agents Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	hemoglobin a1c diabetes mellitus glimepiride hypoglycemic agents Nutritional diseases. Deficiency diseases RC620-627 Alexander Sergeevich Ametov Fatima Totrazovna Abaeva Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
description	Aim. To investigate the efficacy and safety of glimepiride as initial mono-therapy in type 2 diabetes patients (T2DM). Materials and Methods. This is a multi-center, open-label prospective observational study. 245 treatment-naive T2DM patients, who had not achieved glycemic goals on lifestyle therapy during first 12 weeks after the diagnosis, were enrolled in this study. Anti-diabetes treatment was initiated with glimepiride and continued during the 6-month follow-up period. Prescription of the initial dose (1 mg per day) and further dose adjustments were carried out by the attending physician in accordance with the glimepiride data sheet. Dynamics of HbA1c, fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPPG), weight and waist circumference, as well as the incidence of hypoglycemia were the evaluated parameters. Results. The baseline HbA1c (mean: 7.9?0.5%; female: 7.8?0.4% ; male: 8.0?0.6%) was significantly reduced at week 12 (mean 7.2?0.6%, p
format	article
author	Alexander Sergeevich Ametov Fatima Totrazovna Abaeva
author_facet	Alexander Sergeevich Ametov Fatima Totrazovna Abaeva
author_sort	Alexander Sergeevich Ametov
title	Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
title_short	Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
title_full	Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
title_fullStr	Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
title_full_unstemmed	Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus
title_sort	efficacy and safety of glimepiride as initial treatment in russian patients with type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2013
url	https://doaj.org/article/3dd493e044804230a221fbe2dc9499dc
work_keys_str_mv	AT alexandersergeevichametov efficacyandsafetyofglimepirideasinitialtreatmentinrussianpatientswithtype2diabetesmellitus AT fatimatotrazovnaabaeva efficacyandsafetyofglimepirideasinitialtreatmentinrussianpatientswithtype2diabetesmellitus
_version_	1718429577521397760

Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus

Ejemplares similares